Compare Dow Jones Industrial Average ETF (DIA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs TransMedics Group Inc — how do they compare? Dow Jones Industrial Average ETF trades at $516.07 (market cap $45.20B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Dow Jones Industrial Average ETF is far larger — about 16.5× TransMedics Group Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and TransMedics Group Inc for 24 Days on average.
| DIA | TMDX | |
|---|---|---|
Market Cap | $45.20B | $2.74B |
Volume | 4,095,368 | 949,331 |
52-Week High | $542.79 | $150.42 |
52-Week Low | $451.37 | $61.99 |
Typical Hold Time | 104 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $516.07, up 0.99% with bearish technical signals from moving averages. The ETF maintains dividend distributions with three recent payouts scheduled through October 2026. Market sentiment reflects broader volatility concerns amid economic uncertainty and Fed policy speculation.
The ETF's outlook remains tied to Dow component performance, with technical resistance at $516 limiting near-term upside. Dividend consistency provides income stability, though bearish momentum and market-wide pressures pose headwinds for large-cap value exposure.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
